Compare AIP & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | ALVO |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | AIP | ALVO |
|---|---|---|
| Price | $28.74 | $3.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $16.83 | $8.00 |
| AVG Volume (30 Days) | ★ 591.9K | 333.2K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,579,000.00 | N/A |
| Revenue This Year | $30.24 | $13.28 |
| Revenue Next Year | $19.50 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | ★ 22.27 | N/A |
| 52 Week Low | $6.64 | $3.03 |
| 52 Week High | $29.50 | $11.85 |
| Indicator | AIP | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 81.99 | 49.40 |
| Support Level | $12.96 | $3.03 |
| Resistance Level | N/A | $3.93 |
| Average True Range (ATR) | 1.43 | 0.16 |
| MACD | 0.49 | 0.01 |
| Stochastic Oscillator | 93.07 | 47.86 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum its revenue from Asia Pacific.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.